vs
Healthpeak Properties（DOC）与德康医疗（DXCM）财务数据对比。点击上方公司名可切换其他公司
德康医疗的季度营收约是Healthpeak Properties的1.8倍（$1.3B vs $719.4M），Healthpeak Properties净利率更高（73.2% vs 21.2%，领先52.0%），德康医疗同比增速更快（21.6% vs 3.1%），过去两年德康医疗的营收复合增速更高（12.0% vs 8.9%）
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
DOC vs DXCM — 直观对比
营收规模更大
DXCM
是对方的1.8倍
$719.4M
营收增速更快
DXCM
高出18.5%
3.1%
净利率更高
DOC
高出52.0%
21.2%
两年增速更快
DXCM
近两年复合增速
8.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $719.4M | $1.3B |
| 净利润 | $114.0M | $267.3M |
| 毛利率 | — | 62.9% |
| 营业利润率 | 17.4% | 25.6% |
| 净利率 | 73.2% | 21.2% |
| 营收同比 | 3.1% | 21.6% |
| 净利润同比 | 2406.4% | 153.6% |
| 每股收益（稀释后） | $0.16 | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCDXCM
| Q1 26 | — | $1.3B | ||
| Q4 25 | $719.4M | $1.3B | ||
| Q3 25 | $705.9M | $1.2B | ||
| Q2 25 | $694.3M | $1.2B | ||
| Q1 25 | $702.9M | $1.0B | ||
| Q4 24 | $698.0M | $1.1B | ||
| Q3 24 | $700.4M | $994.2M | ||
| Q2 24 | $695.5M | $1.0B |
净利润DOCDXCM
| Q1 26 | — | $267.3M | ||
| Q4 25 | $114.0M | $267.3M | ||
| Q3 25 | $-117.1M | $283.8M | ||
| Q2 25 | $31.7M | $179.8M | ||
| Q1 25 | $42.8M | $105.4M | ||
| Q4 24 | $4.5M | $151.7M | ||
| Q3 24 | $85.9M | $134.6M | ||
| Q2 24 | $146.0M | $143.5M |
毛利率DOCDXCM
| Q1 26 | — | 62.9% | ||
| Q4 25 | — | 62.9% | ||
| Q3 25 | 58.6% | 60.5% | ||
| Q2 25 | 60.2% | 59.5% | ||
| Q1 25 | 61.1% | 56.9% | ||
| Q4 24 | 60.3% | 58.9% | ||
| Q3 24 | 60.0% | 59.7% | ||
| Q2 24 | 60.6% | 62.4% |
营业利润率DOCDXCM
| Q1 26 | — | 25.6% | ||
| Q4 25 | 17.4% | 25.6% | ||
| Q3 25 | 9.2% | 20.1% | ||
| Q2 25 | 5.7% | 18.4% | ||
| Q1 25 | 7.7% | 12.9% | ||
| Q4 24 | -2.2% | 17.0% | ||
| Q3 24 | 14.1% | 15.3% | ||
| Q2 24 | 22.3% | 15.7% |
净利率DOCDXCM
| Q1 26 | — | 21.2% | ||
| Q4 25 | 73.2% | 21.2% | ||
| Q3 25 | -16.6% | 23.5% | ||
| Q2 25 | 4.6% | 15.5% | ||
| Q1 25 | 6.1% | 10.2% | ||
| Q4 24 | 0.7% | 13.6% | ||
| Q3 24 | 12.3% | 13.5% | ||
| Q2 24 | 21.0% | 14.3% |
每股收益（稀释后）DOCDXCM
| Q1 26 | — | $0.67 | ||
| Q4 25 | $0.16 | $0.67 | ||
| Q3 25 | $-0.17 | $0.70 | ||
| Q2 25 | $0.05 | $0.45 | ||
| Q1 25 | $0.06 | $0.27 | ||
| Q4 24 | $0.02 | $0.37 | ||
| Q3 24 | $0.12 | $0.34 | ||
| Q2 24 | $0.21 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $467.5M | $917.7M |
| 总债务越低越好 | $9.8B | — |
| 股东权益账面价值 | $7.5B | $2.7B |
| 总资产 | $20.3B | $6.3B |
| 负债/权益比越低杠杆越低 | 1.31× | — |
8季度趋势，按日历期对齐
现金及短期投资DOCDXCM
| Q1 26 | — | $917.7M | ||
| Q4 25 | $467.5M | $917.7M | ||
| Q3 25 | $91.0M | $1.8B | ||
| Q2 25 | $89.4M | $1.2B | ||
| Q1 25 | $70.6M | $904.9M | ||
| Q4 24 | $119.8M | $606.1M | ||
| Q3 24 | $180.4M | $621.2M | ||
| Q2 24 | $106.9M | $939.2M |
总债务DOCDXCM
| Q1 26 | — | — | ||
| Q4 25 | $9.8B | — | ||
| Q3 25 | $9.1B | — | ||
| Q2 25 | $9.0B | — | ||
| Q1 25 | $8.9B | — | ||
| Q4 24 | $8.7B | — | ||
| Q3 24 | $8.6B | — | ||
| Q2 24 | $8.6B | — |
股东权益DOCDXCM
| Q1 26 | — | $2.7B | ||
| Q4 25 | $7.5B | $2.7B | ||
| Q3 25 | $7.6B | $2.7B | ||
| Q2 25 | $7.9B | $2.6B | ||
| Q1 25 | $8.2B | $2.3B | ||
| Q4 24 | $8.4B | $2.1B | ||
| Q3 24 | $8.6B | $2.0B | ||
| Q2 24 | $8.8B | $2.4B |
总资产DOCDXCM
| Q1 26 | — | $6.3B | ||
| Q4 25 | $20.3B | $6.3B | ||
| Q3 25 | $19.6B | $7.5B | ||
| Q2 25 | $19.8B | $7.3B | ||
| Q1 25 | $19.8B | $6.8B | ||
| Q4 24 | $19.9B | $6.5B | ||
| Q3 24 | $20.0B | $6.4B | ||
| Q2 24 | $20.2B | $6.8B |
负债/权益比DOCDXCM
| Q1 26 | — | — | ||
| Q4 25 | 1.31× | — | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 1.04× | — | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.98× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3B | — |
| 自由现金流经营现金流 - 资本支出 | $357.0M | — |
| 自由现金流率自由现金流/营收 | 49.6% | — |
| 资本支出强度资本支出/营收 | 124.4% | — |
| 现金转化率经营现金流/净利润 | 10.99× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DOCDXCM
| Q1 26 | — | — | ||
| Q4 25 | $1.3B | $294.0M | ||
| Q3 25 | $315.0M | $659.9M | ||
| Q2 25 | $363.5M | $303.0M | ||
| Q1 25 | $279.4M | $183.8M | ||
| Q4 24 | $1.1B | $301.4M | ||
| Q3 24 | $318.2M | $199.5M | ||
| Q2 24 | $316.2M | $279.4M |
自由现金流DOCDXCM
| Q1 26 | — | — | ||
| Q4 25 | $357.0M | $192.1M | ||
| Q3 25 | — | $579.4M | ||
| Q2 25 | — | $208.9M | ||
| Q1 25 | — | $96.8M | ||
| Q4 24 | $333.7M | $176.8M | ||
| Q3 24 | — | $88.3M | ||
| Q2 24 | — | $213.3M |
自由现金流率DOCDXCM
| Q1 26 | — | — | ||
| Q4 25 | 49.6% | 15.3% | ||
| Q3 25 | — | 47.9% | ||
| Q2 25 | — | 18.1% | ||
| Q1 25 | — | 9.3% | ||
| Q4 24 | 47.8% | 15.9% | ||
| Q3 24 | — | 8.9% | ||
| Q2 24 | — | 21.2% |
资本支出强度DOCDXCM
| Q1 26 | — | — | ||
| Q4 25 | 124.4% | 8.1% | ||
| Q3 25 | — | 6.7% | ||
| Q2 25 | — | 8.1% | ||
| Q1 25 | — | 8.4% | ||
| Q4 24 | 105.6% | 11.2% | ||
| Q3 24 | — | 11.2% | ||
| Q2 24 | — | 6.6% |
现金转化率DOCDXCM
| Q1 26 | — | — | ||
| Q4 25 | 10.99× | 1.10× | ||
| Q3 25 | — | 2.33× | ||
| Q2 25 | 11.48× | 1.69× | ||
| Q1 25 | 6.52× | 1.74× | ||
| Q4 24 | 235.43× | 1.99× | ||
| Q3 24 | 3.71× | 1.48× | ||
| Q2 24 | 2.17× | 1.95× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
